CY1112527T1 - Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin - Google Patents

Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin

Info

Publication number
CY1112527T1
CY1112527T1 CY20121100190T CY121100190T CY1112527T1 CY 1112527 T1 CY1112527 T1 CY 1112527T1 CY 20121100190 T CY20121100190 T CY 20121100190T CY 121100190 T CY121100190 T CY 121100190T CY 1112527 T1 CY1112527 T1 CY 1112527T1
Authority
CY
Cyprus
Prior art keywords
amiodarone
cyclodextrin
compositions
sulfoalkyl ether
composition
Prior art date
Application number
CY20121100190T
Other languages
English (en)
Inventor
Gerold L Mosher
Karen T Johnson
Atef A Gayed
Original Assignee
Cydex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals, Inc. filed Critical Cydex Pharmaceuticals, Inc.
Publication of CY1112527T1 publication Critical patent/CY1112527T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει υδατικές παρεντερικές συνθέσεις που περιέχουν ένα αντί-αρρυθμικό παράγοντα, όπως amiodarone, και μία sulfoalkyl ether cyclodextrin. Οι υγρές συνθέσεις είναι διαυγείς, μπορούν να αποστειρωθούν και είναι χημικά και φυσικά ευσταθείς. Οι υγρές συνθέσεις δεν απαιτούν ένα τασιενεργό υλικό και δεν καθιζάνουν κατά την αραίωση με απεσταγμένο νερό ή άλλο φαρμακευτικά αποδεκτό υγρό φορέα. Η σύνθεση που περιέχει sulfoalkyl ether cyclodextrin παρέχει σημαντικά πλεονεκτήματα έναντι άλλων συνθέσεων του amiodarone που περιέχουν κυκλοδεξτρίνη (cyclodextrin). H σύνθεση μπορεί να παρασκευαστεί μέσα σε όξινο, ουδέτερο και ελαφρώς βασικό μέσο, ενώ παρέχει αποδεκτές συγκεντρώσεις του amiodarone κατάλληλες για παρεντερική χορήγηση. Μία σύνθεση του amiodarone που περιέχει SΑΕ-CD μπορεί να παρασχεθεί σε υγρή μορφή ή σαν σκόνη που μπορεί να ανασυσταθεί. Επί πλέον, μπορούν να παρασκευαστούν συμπυκνωμένα διαλύματα που υπερβαίνουν τα 200 mg amiodarone ανά mL. Τα διαλύματα μπορούν να κατασκευαστούν είτε αραιώσιμα ή μη αραιώσιμα με νερό σε θερμοκρασία δωματίου υπό συνθήκες που συναντώνται τυπικά στην κλινική.
CY20121100190T 2002-05-04 2012-02-23 Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin CY1112527T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/139,620 US6869939B2 (en) 2002-05-04 2002-05-04 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
EP03728598A EP1501496B1 (en) 2002-05-04 2003-04-29 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin

Publications (1)

Publication Number Publication Date
CY1112527T1 true CY1112527T1 (el) 2015-12-09

Family

ID=29399340

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100190T CY1112527T1 (el) 2002-05-04 2012-02-23 Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin

Country Status (16)

Country Link
US (1) US6869939B2 (el)
EP (2) EP2402008B1 (el)
JP (2) JP4764004B2 (el)
KR (1) KR100984197B1 (el)
AT (1) ATE535239T1 (el)
AU (1) AU2003234285B2 (el)
CA (1) CA2483774C (el)
CY (1) CY1112527T1 (el)
DK (2) DK1501496T3 (el)
ES (2) ES2378306T3 (el)
HU (1) HUE027551T2 (el)
IL (2) IL165022A0 (el)
MX (1) MXPA04010925A (el)
PT (1) PT1501496E (el)
SI (2) SI1501496T1 (el)
WO (1) WO2003092590A2 (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5021318B2 (ja) 2004-01-30 2012-09-05 ファイザー・プロダクツ・インク β−シクロデキストリンを液体投薬形態に用いて多用量製剤を達成するための抗菌性防腐剤
RU2006141358A (ru) 2004-04-23 2008-05-27 Сайдекс, Инк. (Us) Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина
CA2565980A1 (en) 2004-05-12 2005-12-01 Luca Technologies, Llc Generation of hydrogen from hydrocarbon-bearing materials
US7426960B2 (en) 2005-05-03 2008-09-23 Luca Technologies, Inc. Biogenic fuel gas generation in geologic hydrocarbon deposits
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7416879B2 (en) 2006-01-11 2008-08-26 Luca Technologies, Inc. Thermacetogenium phaeum consortium for the production of materials with enhanced hydrogen content
US20070232567A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
JP5823093B2 (ja) * 2006-03-28 2015-11-25 ジャヴェリン ファーマシューティカルズ インコーポレイテッド 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物
US7977282B2 (en) 2006-04-05 2011-07-12 Luca Technologies, Inc. Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material
US7696132B2 (en) * 2006-04-05 2010-04-13 Luca Technologies, Inc. Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
EP2061458B1 (en) * 2006-09-15 2014-12-10 Regents of the University of Minnesota Topiramate compositions and methods for their use
US20090270496A1 (en) * 2007-05-03 2009-10-29 Courchesne William E Antifungal compounds
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US8479813B2 (en) 2009-12-16 2013-07-09 Luca Technologies, Inc. Biogenic fuel gas generation in geologic hydrocarbon deposits
EP2335686A1 (en) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
NL2004260C2 (en) * 2010-02-18 2011-08-22 Univ Amsterdam Disinfectant composition and its use in dental treatment.
US20120142768A1 (en) 2010-06-11 2012-06-07 Baxter Healthcare S.A. Formulations including amiodarone and salts thereof and methods of their manufacture and use
DK2734212T3 (da) 2011-07-20 2017-11-06 Hospira Inc Sammensætninger omfattende diclofenac til behandling af postoperativ smerte
US9492552B2 (en) * 2011-11-29 2016-11-15 Jurox Pty Ltd Injectable aqueous pharmaceutical compositions comprising a cyclodextrin, a hydrophobic drug, a co-solvent, and a preservative
EP3415153A1 (en) * 2012-01-30 2018-12-19 Baxalta GmbH Non-anticoagulant sulfated or sulfonated polysaccharides
DK3702374T3 (da) 2012-02-15 2022-06-27 Cydex Pharmaceuticals Inc Fremsgangsmåde til fremstilling for cyclodextrin-derivater
KR20200106100A (ko) 2012-02-28 2020-09-10 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
US9004162B2 (en) 2012-03-23 2015-04-14 Transworld Technologies Inc. Methods of stimulating acetoclastic methanogenesis in subterranean deposits of carbonaceous material
US20150258202A1 (en) * 2012-10-17 2015-09-17 Sapiotec Gmbh Anthocyanidin complex for the treatment of multiple myeloma
CA2888822C (en) 2012-10-22 2021-01-26 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
JP6235603B2 (ja) * 2012-11-15 2017-11-22 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ 消炎性および／または免疫抑制性活性成分としてのデルフィニジン複合体
EP2773033B1 (en) 2013-02-28 2018-12-05 Dialog Semiconductor GmbH Divide by 2 and 3 charge pump methods
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
WO2016029179A1 (en) 2014-08-22 2016-02-25 Cydex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
US10736891B2 (en) 2016-01-07 2020-08-11 Roy MADIGAN Composition and method for treating chagas disease
US11166911B2 (en) * 2016-03-04 2021-11-09 Sun Pharmaceutical Industries Limited Parenteral dosage form of amiodarone
CN107753439A (zh) * 2016-08-22 2018-03-06 黑龙江迪龙制药有限公司 一种注射用盐酸胺碘酮及其制备方法
JP2019535722A (ja) 2016-11-18 2019-12-12 アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾シクロデキストリン及び酸性化剤に基づくアミジン置換ベータ−ラクタム化合物の新規製剤、それらの製造及び抗菌医薬組成物としての使用
EP3968979A4 (en) * 2019-05-15 2023-03-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
WO2021026310A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
CN115969833A (zh) * 2023-01-03 2023-04-18 上海上药第一生化药业有限公司 胺碘酮药物组合物、注射液及其制备方法及含其的注射器

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491812A4 (en) 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0518930A4 (en) 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
US5234949A (en) 1992-04-01 1993-08-10 Academic Pharmaceuticals, Inc. Parenteral solutions containing amiodarone in acetate buffer solution
FR2735978B1 (fr) * 1995-06-30 1997-09-19 Sanofi Sa Composition pharmaceutique d'amiodarone pour administration parenterale
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
KR100708360B1 (ko) * 1999-01-21 2007-04-17 브리스톨-마이어스스퀴브컴파니 라스-파르네실트란스퍼라제 억제제와술포부틸에테르-7-β-시클로덱스트린 또는2-히드록시프로필-β-시클로덱스트린과의 착물 및 방법
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9921958D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
US6479541B1 (en) * 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration

Also Published As

Publication number Publication date
JP2011116776A (ja) 2011-06-16
KR20040106452A (ko) 2004-12-17
EP2402008B1 (en) 2016-01-27
CA2483774C (en) 2011-07-19
US6869939B2 (en) 2005-03-22
JP4764004B2 (ja) 2011-08-31
ES2378306T3 (es) 2012-04-11
AU2003234285A1 (en) 2003-11-17
US20030216353A1 (en) 2003-11-20
SI2402008T1 (sl) 2016-05-31
KR100984197B1 (ko) 2010-09-28
PT1501496E (pt) 2012-02-20
IL165022A (en) 2011-08-31
EP1501496B1 (en) 2011-11-30
MXPA04010925A (es) 2005-02-14
JP2005530744A (ja) 2005-10-13
WO2003092590A2 (en) 2003-11-13
ES2567716T3 (es) 2016-04-26
CA2483774A1 (en) 2003-11-13
IL165022A0 (en) 2005-12-18
WO2003092590A3 (en) 2004-01-22
EP2402008A1 (en) 2012-01-04
EP1501496A2 (en) 2005-02-02
EP1501496A4 (en) 2006-05-31
SI1501496T1 (sl) 2012-04-30
DK2402008T3 (en) 2016-05-02
ATE535239T1 (de) 2011-12-15
JP5656692B2 (ja) 2015-01-21
HUE027551T2 (en) 2016-10-28
AU2003234285B2 (en) 2007-01-04
DK1501496T3 (da) 2012-03-19

Similar Documents

Publication Publication Date Title
CY1112527T1 (el) Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin
AR037755A1 (es) Composiciones acuosas con contenido de metronidazol
CY1119806T1 (el) Συνθεσεις που περιλαμβανουν δροσπιρενονη και ενα συμπλοκο μεταξυ αιθινυλοιστραδιολης και μιας κυκλοδεξτρινης
CY1107506T1 (el) Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης
CY1114631T1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
BR0209862A (pt) Imunoconjugados de anticorpos de cd44 citotóxicos
EP1472230A4 (en) ANSAMYCINS WITH IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES
ITRM20010464A1 (it) Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
ATE274913T1 (de) Wässerige zusammensetzung enthaltend amphotericin b
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
PT1299107E (pt) Solucoes estaveis muito concentradas de meloxicam
CY1113461T1 (el) Μη συνεζευγμενο χολικο οξυ μαζι με propyl gallate και/ή βηα για την αυξηση της απορροφησης μακρο-μοριων
NO20014101L (no) Stabilisert oral farmasöytisk blanding inneholdende iodid og iodat og fremgangsmåte
TR200201683T2 (tr) İkameli fenil-piperazin türevleri, bunların hazırlanması ve kullanımları
MY135548A (en) Aqueous preparation containing oligopeptides and etherified cyclodextrin
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
BR9900114A (pt) Composições de ciclodextrina.
ATE317695T1 (de) Parenterale lösung enthaltend amiodaron
CY1105345T1 (el) Φαινυλαλκινια
DE69933388D1 (de) Pharmazeutische Lösungen VON TRIPHENYLETHYLEN-ANTIÖSTROGENEN
GB9901253D0 (en) Bis-terpyridine-platinum(II) complexes
DK1087973T3 (da) Imidazotriazolopyrimidiner som lægemiddel med adenosinantagonist effekt
IT1318640B1 (it) Derivati di carnosina, procedimento per la loro preparazione ecomposizioni farmaceutiche che li contengono.